Big Pharma is currently waging a fierce lobbying battle to protect its monopoly patent rights for COVID-19 vaccines and treatments. While Corporate Europe Observatory broadly outlines the sector’s lobby spending, this is likely to be an underestimate of Big Pharma’s true firepower; and up-to-date lobbying information and details are hard to come by. Weak EU lobby transparency rules are hampering the public scrutiny that is more needed than ever now during the pandemic.
Read here
Be the first to comment